Scientists uncover that albumin is prevented from crossing the placenta – open opportunities for design of long-acting biologic medicines with limited fetal exposure
Peer-Reviewed Publication
Updates every hour. Last Updated: 3-Nov-2026 22:16 ET (4-Nov-2026 03:16 GMT/UTC)
Biologic medicines have transformed the treatment of cancer, autoimmune diseases, migraine, inflammatory disorders and many other diseases. Yet, their growing use among women of reproductive age constitutes a major clinical challenge in that therapeutic IgG antibodies are actively transported across the placenta to the developing fetus. Evidence that supports safe use of such therapeutics during pregnancy remains limited.
Now, researchers from the University of Oslo and Oslo University Hospital, together with national and international collaborators, have uncovered that the placenta distinguishes between antibodies and albumin, a finding that may reshape the future design of biologic medicines with reduced fetal exposure.
MIT researchers showed that blocking caspase-1, an enzyme involved in lung inflammation, appears to reduce the risk of developing tumors. The enzyme-blocking drug might help prevent lung cancer in people at high risk for the disease.
The foundation DKMS Stiftung Leben Spenden has opened the new application round for the DKMS John Hansen Research Grant. Up to four outstanding projects by early-career researchers worldwide will be funded, with each receiving up to €240,000 over a three-year period. The focus is on research projects related to hematopoietic stem cell transplantation and cell therapy for hematological diseases. Applications for the DKMS John Hansen Research Grant 2027 can be submitted through November 16, 2026.
A new University of Kent spin-out has been launched to commercialise biotechnology that could make it cheaper and easier to produce proteins used in cancer treatments, vaccines and diagnostics tests.